The broader societal benefits offered by new technologies in terms of quality-adjusted life-years (QALYs) accrued by carers (e.g., a partner, parent, or family member) are accepted for inclusion in the Reference Case for National Institute for Health and Care Excellence (NICE) technology appraisals (TAs) and highly specialised technology (HST) guidance. The research presented here reviews all published TAs and HST assessments to identify those that considered the impact of an intervention on QALYs for carers and how these have incorporated carer health-related quality of life (HRQoL). We reviewed all TAs and HST assessments published between April 2013, when the current NICE methods guidance was issued, and July 2020. Manufacturers included carer HRQoL in their economic models in 5% (17/331) of NICE TAs and HST assessments. Most of these (9/17) concerned neurological conditions; 7/9 were for multiple sclerosis, 6 of which used utility decrements for carers of patients with Alzheimer’s disease. In 2/17 submissions, carer disutilities were derived using vignettes valued through the EuroQol five-dimension questionnaire (EQ-5D) visual analogue scale (VAS). One submission included the QALY loss to a family due to the premature death of a child. The remaining studies used disutilities from the literature. Of the 17 submissions, 9 included carer HRQoL in the base case only, and 2 in the base case and scenario analyses. NICE accepted inclusion of disutilities for carers in all of these. Six included carer HRQoL only in a scenario analysis. NICE rejected 4 of them. Carer HRQoL benefits/analyses are not routinely submitted for NICE decision-making. In the cases where NICE accepted it, various methodologies were applied besides EQ-5D to derive utility decrements. NICE should provide further guidance and evidence to support a consistent approach to including carer/family health outcomes in appraisals.